Replies to post #239089 on Biotech Values

[vinmantoo]

Jay Luly re-iterated that ENTA is looking at other (non-protease) MoAs against SARS-CoV-2, but he would not disclose which ones. He thinks monotherapy may be sufficient for acute treatment.

Thanks Dew! I just read the transcript. Smart to have other irons in the fire just in case.